Sodium homeostasis is preserved in a global 11β-hydroxysteroid dehydrogenase type 1 knockout mouse model

Experimental Physiology
Thorbjørn H ChristensenRobert W Hunter

Abstract

What is the central question of this study? Glucocorticoids act in the kidney to promote salt and water retention. Renal 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1), by increasing local concentrations of glucocorticoids, may exert an antinatriuretic effect. We hypothesized that global deletion of 11βHSD1 in the mouse would give rise to a salt-wasting renal phenotype. What is the main finding and its importance? We subjected a mouse model of global 11βHSD1 deletion to studies of water and electrolyte balance, renal clearance, urinary steroid excretion, renin-angiotensin system activation and renal sodium transporter expression. We found no significant effects on renal sodium or water excretion. Any effect of renal 11βHSD1 on sodium homeostasis is subtle. Glucocorticoids act in the kidney to regulate glomerular haemodynamics and tubular sodium transport; the net effect favours sodium retention. 11β-Hydroxysteroid dehydrogenase type 1 (11βHSD1) is expressed in the renal tubules and the interstitial cells of the medulla, where it is likely to regenerate active glucocorticoids from inert 11-keto forms. The physiological function of renal 11βHSD1 is largely unknown. We hypothesized that loss of renal 11βHSD1 would result in sal...Continue Reading

References

May 1, 1979·The Journal of Cell Biology·J B WadeE L Boulpaep
Feb 7, 1998·Proceedings of the National Academy of Sciences of the United States of America·Y KotelevtsevJ J Mullins
Mar 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·S Y ChenD Pearce
Sep 10, 2002·American Journal of Physiology. Renal Physiology·Shyama MasilamaniMark A Knepper
Jul 4, 2003·The Journal of Clinical Investigation·Hiroaki MasuzakiJeffrey S Flier
Mar 12, 2004·Nephrology·George J MangosJohn J Kelly
May 1, 2004·Proceedings of the National Academy of Sciences of the United States of America·Janice M PatersonJohn J Mullins
Sep 13, 2008·Pflügers Archiv : European journal of physiology·S K InglisS M Wilson
May 28, 2009·The Journal of Clinical Endocrinology and Metabolism·Panagiotis AnagnostisDimitri P Mikhailidis
Jun 28, 2011·Lancet·Abd A TahraniAnthony H Barnett
Aug 9, 2011·Molecular and Cellular Endocrinology·Alex Odermatt, Denise V Kratschmar
Oct 21, 2011·American Journal of Physiology. Renal Physiology·Gustavo Frindt, Lawrence G Palmer
Jun 2, 2012·Metabolism: Clinical and Experimental·Panagiotis AnagnostisDimitri P Mikhailidis
Aug 1, 2013·Physiological Reviews·Karen ChapmanJonathan Seckl
Jan 10, 2014·American Journal of Physiology. Renal Physiology·Robert W HunterMatthew A Bailey
Feb 19, 2014·The Journal of Physiology·Robert W HunterMatthew A Bailey
Mar 13, 2014·Clinical Endocrinology·David E Henley, Stafford L Lightman
Jun 4, 2014·Proceedings of the National Academy of Sciences of the United States of America·Stuart A MorganGareth G Lavery
Oct 29, 2014·Journal of the American Society of Nephrology : JASN·Robert W HunterJohn J Mullins

❮ Previous
Next ❯

Citations

Nov 16, 2017·Current Hypertension Reports·Matthew A Bailey
Nov 11, 2017·The Journal of Biological Chemistry·Charlotte BuckleyJohn J Mullins

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.